BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 7563210)

  • 21. [Docetaxel in the adjuvant treatment of operable breast carcinoma. News from ASCO 2002].
    Montemurro F
    Tumori; 2002; 88(4):A1-7. PubMed ID: 12402832
    [No Abstract]   [Full Text] [Related]  

  • 22. Taxane-based therapy for breast cancer: combination or sequential therapy?
    Sparano JA; Rajdev L
    Cancer Invest; 2000; 18(5):498-500. PubMed ID: 10834036
    [No Abstract]   [Full Text] [Related]  

  • 23. [Role of taxanes in treatment of breast cancer].
    Gorbunova VA; Besova NS
    Vopr Onkol; 2004; 50(4):492-500. PubMed ID: 15605777
    [No Abstract]   [Full Text] [Related]  

  • 24. Paclitaxel plus doxorubicin in metastatic breast Ca: the Milan experience.
    Gianni L
    Oncology (Williston Park); 1998 Jan; 12(1 Suppl 1):13-5. PubMed ID: 9516596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of taxanes as a component of neoadjuvant chemotherapy for breast cancer.
    Gogas H; Fountzilas G
    Ann Oncol; 2003 May; 14(5):667-74. PubMed ID: 12702519
    [No Abstract]   [Full Text] [Related]  

  • 26. Optimal chemotherapy for women with breast cancer: the plot thickens.
    Pater JL; Pritchard KI
    J Clin Oncol; 2003 Mar; 21(6):963-4. PubMed ID: 12637457
    [No Abstract]   [Full Text] [Related]  

  • 27. In vitro modulation of doxorubicin and docetaxel antitumoral activity by methyl-beta-cyclodextrin.
    Grosse PY; Bressolle F; Pinguet F
    Eur J Cancer; 1998 Jan; 34(1):168-74. PubMed ID: 9624253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A case of docetaxel-resistant breast cancer responsive to paclitaxel therapy].
    Oura S; Tanino H; Yoshimasu T; Sakurai T; Nakamura T; Kokawa Y; Matsuyama K; Naito Y
    Gan To Kagaku Ryoho; 2001 Apr; 28(4):511-4. PubMed ID: 11329786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integration of docetaxel into adjuvant breast cancer treatment regimens.
    Hortobagyi GN
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):27-33. PubMed ID: 12108895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review of docetaxel/doxorubicin combination in metastatic breast cancer.
    DiƩras V
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):31-3. PubMed ID: 9364539
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancer.
    Ravdin PM
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):20-3. PubMed ID: 10426455
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Docetaxel symposium].
    Viens P
    Bull Cancer; 1997 Aug; 84(8):833-4. PubMed ID: 9339190
    [No Abstract]   [Full Text] [Related]  

  • 33. [Progress and perspectives in palliative therapy of breast carcinoma].
    Verlag GT
    Dtsch Med Wochenschr; 1996 Dec; 121(49 Suppl):1-8. PubMed ID: 8983911
    [No Abstract]   [Full Text] [Related]  

  • 34. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial.
    Heys SD; Hutcheon AW; Sarkar TK; Ogston KN; Miller ID; Payne S; Smith I; Walker LG; Eremin O;
    Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S69-74. PubMed ID: 12435290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
    Nabholtz JM; Smylie M; Mackey JR; Noel D; Paterson AH; al-Tweigeri T; Au D; Sansregret E; Delorme F; Riva A
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):37-41. PubMed ID: 9364541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A clinical study of taxotere versus taxotere plus the antiprolactinemic agent bromocriptine in metastatic breast cancer pretreated with anthracyclines.
    Lissoni P; Bucovec R; Malugani F; Ardizzoia A; Villa S; Gardani GS; Vaghi M; Tancini G
    Anticancer Res; 2002; 22(2B):1131-4. PubMed ID: 12168912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
    Valero V; Holmes FA; Walters RS; Theriault RL; Esparza L; Fraschini G; Fonseca GA; Bellet RE; Buzdar AU; Hortobagyi GN
    J Clin Oncol; 1995 Dec; 13(12):2886-94. PubMed ID: 8523051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase III randomized trials of docetaxel in patients with metastatic breast cancer.
    Crown J
    Semin Oncol; 1999 Jun; 26(3 Suppl 8):33-8. PubMed ID: 10403472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer.
    Costa SD; von Minckwitz G; Raab G; Blohmer JU; Dresel V; Eidtmann H; Hilfrich J; Jackisch C; Merkle E; Gademann G; Kaufmann M
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):24-31. PubMed ID: 10426456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single-agent docetaxel (Taxotere) in randomized phase III trials.
    Burris HA
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):1-6. PubMed ID: 10426452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.